BCM
KZR

BlueCrest Capital Management’s Kezar Life Sciences KZR Stock Holding History

BlueCrest Capital Management’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-976
Closed -$209K – 1169
2018
Q3 		$209K Buy
+976
New +$170K 0.01% 1248

Other funds holding KZR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

BlueCrest Capital Management's KZR Position: Q4 2018 in Review

BlueCrest Capital Management sold out of Kezar Life Sciences (KZR) in Q4 2018, closing a stake of 976 shares — an estimated $209K sold.

BlueCrest Capital Management first reported a position in KZR in Q3 2018 and held it in 1 quarter. The position peaked at $209K in Q3 2018. 39 funds tracked by Wall St. Rank hold KZR as of Q4 2018.

  • BlueCrest Capital Management reported no remaining Kezar Life Sciences position as of Q4 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 976 Kezar Life Sciences shares in Q4 2018, an estimated $209K.
  • BlueCrest Capital Management first reported a position in Kezar Life Sciences in Q3 2018 and held it in 1 quarter.
  • BlueCrest Capital Management's Kezar Life Sciences position peaked at $209K in Q3 2018.
  • 39 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.